Isolated unconjugated hyperbilirubinemia in adults: the Gilbert’s versus Criggler Najar Syndrome Type 2 conundrum.

Abstract

Gilbert’s syndrome is a genetic disorder characterised by non-hemolytic unconjugated hyperbilirubinemia. It is caused by mutations in the UGT1A1 gene which codes for the enzyme uridine diphosphate glucoronosyl transferase-1, which conjugates bilirubin for excretion. Affected individuals are usually asymptomatic apart from a mild jaundice and investigations reveal a mild isolated indirect hyperbilirubinemia. This may be exacerbated in the face of environmental and physical stressors. It is very similar in presentation to Criggler-Najjar syndrome (CNS) type 2. There is a small risk of kernicterus in patients with CNS type 2 needing daily phenobarbitone therapy. This risk is miniscule in Gilbert’s syndrome. Genetic testing for polymorphisms of the UGT1A1 gene is the diagnostic clincher for Gilbert’s syndrome, but it can also be picked up by evaluating the response to phenobarbitone and fasting, particularly in resource poor settings. Due to limited availability, case reports documenting the genetic mutational analysis are sparse. We reported one such rare case with an unusually high indirect hyperbilirubinemia in Gilbert’s syndrome confirmed by both phenobarbitone response and genetic analysis.

Keywords

• Gilbert’s
• isolated indirect hyperbilirubinemia
• Phenobarbitone

References

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004 Oct;4(10):757-68. doi: 10.1038/nrc1452.
2. Krugmann J, Tzankov A, Fiegl M, Dirnhofer S, Siebert R, Erdel M. Burkitt’s lymphoma of the stomach: a case report with molecular cytogenetic analysis. Leuk Lymphoma. 2004 May;45(5):1055-9. doi: 10.1080/10428190310001623847.
3. Jang SJ, Yoon DH, Kim S, Yoon S, Kim DY, Park CS, Huh J, Lee SW, Lee DH, Ryu JS, Suh C. A unique pattern of extranodal involvement in Korean adults with sporadic Burkitt lymphoma: a single center experience. Ann Hematol. 2012 Dec;91(12):1917-22. doi: 10.1007/s00277-012-1531-1.
4. Sekiguchi Y, Yoshikawa H, Shimada A, Imai H, Wakabayashi M, Sugimoto K, Nakamura N, Sawada T, Takeuchi K, Ohta Y, Komatsu N, Noguchi M. Primary hepatic circumscribed Burkitt’s lymphoma that developed after acute hepatitis B: report of a case with a review of the literature. J Clin Exp Hematop. 2013;53(2):167-73. doi: 10.3960/jslrt.53.167.
5. Erkan G, Çoban M, Çalıskan A, Ataç GK, Gulpınar K, Degertekin B, Korkmaz A. A Burkitt’s lymphoma case mimicking Crohn’s disease:a case report. Case Reports Med. 2011;2011 doi:10.1155/2011/685273.
6. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J, Temmesfeld A, Schmitz R, Rübe C, Probst A, Jaenke G, Bodenstein H, Junker A, Pott C, Schultze J, Heinecke A, Parwaresch R, Tiemann M; German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3861-73. doi:10.1200/JCO.2001.19.18.3861.
7. Magrath IT, Shiramizu B. Biology and treatment of small non-cleaved cell lymphoma. Oncology (Williston Park). 1989 Nov;3(11):41-53.
8. Ferry JA. Burkitt’s lymphoma: Clinicopathologic features and differential diagnosis. Oncologist. 2006;11(4):375-83. doi:10.1634/theoncologist.11-4-375.

9. Lúquez Mindiola A, Otero Regino W, Schmulson M. Diagnostic and therapeutic approach to dyspepsia and functional dyspepsia: what’s new in 2019. Rev Gastroenterol Peru. 2019 Apr-Jun;39(2):141-52 (in Spanish).